KCM
CSTL icon

Kornitzer Capital Management’s Castle Biosciences CSTL Stock Holding History

Kornitzer Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.3M Sell
264,235
-161
-0.1% -$3.59K 0.13% 162
2026
Q1 		$6.49M Sell
264,396
-3,337
-1% -$109K 0.14% 151
2025
Q4 		$10.4M Sell
267,733
-10,581
-4% -$341K 0.22% 108
2025
Q3 		$6.34M Hold
278,314
– – 0.13% 190
2025
Q2 		$5.68M Hold
278,314
– – 0.11% 214
2025
Q1 		$5.57M Sell
278,314
-105,660
-28% -$2.62M 0.11% 211
2024
Q4 		$10.2M Sell
383,974
-23,264
-6% -$709K 0.2% 143
2024
Q3 		$11.6M Sell
407,238
-135,636
-25% -$3.45M 0.21% 131
2024
Q2 		$11.8M Hold
542,874
– – 0.22% 125
2024
Q1 		$12M Hold
542,874
– – 0.22% 138
2023
Q4 		$11.7M Sell
542,874
-105,350
-16% -$1.85M 0.23% 135
2023
Q3 		$10.9M Hold
648,224
– – 0.23% 137
2023
Q2 		$8.89M Hold
648,224
– – 0.17% 190
2023
Q1 		$14.7M Sell
648,224
-68,020
-9% -$1.66M 0.29% 98
2022
Q4 		$16.9M Buy
716,244
+92,048
+15% +$2.13M 0.34% 80
2022
Q3 		$16.3M Sell
624,196
-17,316
-3% -$485K 0.35% 74
2022
Q2 		$14.1M Buy
641,512
+197,170
+44% +$4.58M 0.28% 113
2022
Q1 		$19.9M Hold
444,342
– – 0.33% 99
2021
Q4 		$19M Buy
444,342
+100,525
+29% +$5.25M 0.28% 124
2021
Q3 		$22.9M Hold
343,817
– – 0.35% 86
2021
Q2 		$25.2M Buy
343,817
+77,940
+29% +$5.15M 0.38% 82
2021
Q1 		$18.2M Buy
265,877
+92,115
+53% +$6.92M 0.29% 126
2020
Q4 		$11.7M Buy
173,762
+13,387
+8% +$726K 0.2% 177
2020
Q3 		$8.25M Buy
160,375
+24,895
+18% +$1.11M 0.16% 197
2020
Q2 		$5.11M Buy
+135,480
New +$4.63M 0.1% 249

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kornitzer Capital Management's CSTL Position: Q2 2026 in Review

Kornitzer Capital Management reduced its Castle Biosciences (CSTL) stake by 0.06% in Q2 2026, selling an estimated $3.59K and leaving 264,235 shares worth $6.3M. The position accounts for 0.13% of the portfolio, ranked #162.

Kornitzer Capital Management first reported a position in CSTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $25.2M in Q2 2021. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Kornitzer Capital Management held 264,235 shares of Castle Biosciences worth $6.3M as of Q2 2026.
  • Kornitzer Capital Management sold 161 Castle Biosciences shares in Q2 2026, an estimated $3.59K.
  • Castle Biosciences made up 0.13% of Kornitzer Capital Management's portfolio in Q2 2026, its #162 holding.
  • Kornitzer Capital Management first reported a position in Castle Biosciences in Q2 2020 and has held it in 25 quarters since.
  • Kornitzer Capital Management's Castle Biosciences position peaked at $25.2M in Q2 2021.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Kornitzer Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.